RS-2025-02213273

Phase 1 clinical trial for trans-splicing ribozyme-based RNA editing therapeutics for glioblastoma

Rznomics Inc.

ONCOLOGY | **Phase 1**

Product Type	Gene/Cell Therapy & Nucleic acids
Indication	Glioblastoma (GBM)
Target	hTERT mRNA
MoA(Mechanism of Action)	RZ-001 is a genetically modified replication-incompetent adenoviral vector designed to provide trans-splicing ribozyme-mediated replacement of tumor-specific human telomerase reverse transcriptase (hTERT) mRNA with the therapeutic RNA for herpes simplex virus thymidine kinase (HSVtk). The HSVtk phosphorylates GCV, which is incorporated into the tumor cell's genomic DNA, suppresses DNA replication and results in cell death through apoptosis. 
Competitiveness	Glioblastoma (GBM) has high unmet medical needs due to poor response to standard therapies. Commonly used treatments include Temodar (Merck & Co.) and Avastin (Genentech/Roche)
Development Stage	Phase 1
Route of Administration	Intratumoral (IT) route in conjunction with oral administration of valganciclovir (VGCV), the orally available prodrug of ganciclovir (GCV).

Any unauthorized distribution or reproduction of this material is strictly prohibited.